A new therapy prevents intellectual disability in mouse with phenylketonuria
In conclusion present study testifies the clinical efficacy of rAvPAL treatment in a preclinical model of PKU and the advantages of erythrocytes as carrier of the enzyme in term of frequency of the administrations and prevention of immunological reactions.
Source: Molecular Genetics and Metabolism - Category: Genetics & Stem Cells Source Type: research
More News: Allegra | Allergy & Immunology | Brain | Disability | Genetics | Neurology | Phenylketonuria | Study